Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.

@article{Furuse1995PhaseIS,
  title={Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.},
  author={Kiyoyuki Furuse and Kaoru Kubota and Masaaki Kawahara and Nagahisa Kodama and Mitsumasa Ogawara and Masanori Akira and Shigenori Nakajima and Minoru Takada and Yasuo Kusunoki and Shunichi Negoro},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1995},
  volume={13 4},
  pages={869-75}
}
PURPOSE To evaluate the response rate, toxicity, and 2-year survival rate of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Between July 1989 and October 1990, 65 patients with histologically or cytologically proven unresectable stage III NSCLC without T3N0-1M0 disease were entered onto this study. Sixty-one patients were eligible for response, survival, and toxicity analysis. Chemotherapy consisted of vindesine (3… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…